Safety and Immunogenicity of the Live-Attenuated Quadrivalent Dengue Vaccine V181 Compared With Butantan-DV Among Healthy Adults in Brazil: A Randomized, Double-Blind, Phase 2 Trial
Clinical Infectious Diseases · 2026
DOI: 10.1093/cid/ciag349 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von David Alexanderian und 10 weiteren Autor:innen. Beteiligte Einrichtung: MRL, Merck & Co., Inc., Rahway, New Jersey, USA. Hauptthemen laut MEDLINE: Dengue Vaccines, Dengue, Immunogenicity, Vaccine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp & Dohme LLC, Merck & Co., Inc., Fundação Butantan.
Abstract (Originalsprache)
Background
Dengue is caused by infection with 1 of 4 dengue virus (DENV) serotypes (DENV-1 to DENV-4). V181 and Butantan-Dengue Vaccine (Butantan-DV) are independently developed, single-dose, quadrivalent dengue vaccines based on the same attenuated parental strains.
Methods
In this randomized, double-blind, active comparator–controlled, multisite, phase 2 trial, we compared the safety and immunogenicity of V181 and Butantan-DV in healthy adults in Brazil. The primary immunogenicity objectives were to compare vaccine-induced neutralizing antibody geometric mean titers (GMTs) and seroconversion rates for DENV-1 to DENV-4 at day 28 postvaccination. The primary and secondary safety objectives, respectively, were to assess vaccine-related serious adverse events and the proportion of participants experiencing solicited adverse events through day 28 postvaccination.
Results
Overall, 1364 participants were assigned (1:1) to receive V181 (n = 682) or Butantan-DV (n = 682). At day 28 postvaccination, V181 induced a noninferior immune response to Butantan-DV for DENV-1 and DENV-2 but not DENV-3 and DENV-4, as measured using GMT ratios. Noninferiority was established for all DENV serotypes based on seroconversion rates. Most participants developed a trivalent or tetravalent neutralizing antibody response. Vaccine viremia was detected for each DENV serotype. V181 and Butantan-DV were generally well tolerated.
Conclusions
V181 was immunogenic in adults, and while immunogenicity was noninferior to Butantan-DV for DENV-1 and DENV-2, seroconversion rates were noninferior for DENV-1 to DENV-4. The safety profile of V181 is comparable to that of Butantan-DV and supports its continued evaluation as a single-dose quadrivalent vaccine for dengue prevention. Clinical Trials Registration NCT05710224
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MRL, Merck & Co., Inc., Rahway, New Jersey, USA.
- Infectious Diseases Service, Hospital São Lucas da PUC do Rio Grande do Sul, Porto Alegre, Brazil.
- School of Medicine, Department of Health Sciences, Universidade Federal de Santa Maria, Santa Maria, Brazil.
- Instituto Butantan, São Paulo, Brazil.
ORCID-Profile: Soumya Chatterjee, Alexandre Vargas Schwarzbold, Matthew T Onorato, Germán Áñez
Förderung
- Merck Sharp & Dohme LLC
- Merck & Co., Inc.
- Fundação Butantan
- Butantan-DV
Zitieren
APA
Alexanderian, D., Ramos, F., Chatterjee, S., Schwarzbold, A. V., Loch, A. P., Zanetti, A. C. B., Chen, Q., Martin, J., Onorato, M. T., Áñez, G., & V181-002 Team (2026). Safety and Immunogenicity of the Live-Attenuated Quadrivalent Dengue Vaccine V181 Compared With Butantan-DV Among Healthy Adults in Brazil: A Randomized, Double-Blind, Phase 2 Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag349
Vancouver
Alexanderian D, Ramos F, Chatterjee S, Schwarzbold AV, Loch AP, Zanetti ACB, et al. Safety and Immunogenicity of the Live-Attenuated Quadrivalent Dengue Vaccine V181 Compared With Butantan-DV Among Healthy Adults in Brazil: A Randomized, Double-Blind, Phase 2 Trial. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag349
BibTeX
@article{Alexanderian2026,
author = {Alexanderian, David and Ramos, Fabiano and Chatterjee, Soumya and Schwarzbold, Alexandre Vargas and Loch, Ana Paula and Zanetti, Ariane Cristina Barboza and Chen, Qiuxu and Martin, Jason and Onorato, Matthew T and Áñez, Germán and V181-002 Team, V181-002 Team},
title = {Safety and Immunogenicity of the Live-Attenuated Quadrivalent Dengue Vaccine V181 Compared With Butantan-DV Among Healthy Adults in Brazil: A Randomized, Double-Blind, Phase 2 Trial},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciag349}
}
EUVIMED